SGS Life Sciences Services Becomes a Medidata Raver Accredited Partner
SGS Life Science Services's Biometrics group, one of the largest European data management, statistics and medical writing teams, became a Medidata Rave accredited partner. Medidata Rave is the industry-leading system for capturing, managing and reporting clinical research data, designed to help life science companies optimize their research investments, by efficiently streamlining the clinical trial process.
Medidata’s accreditation programme for Rave is an in-depth qualification programme through both build and process enablement tracks, with the aim for partners to provide end-user training, user and site administration, study build, reporting, outputs and migration services. Implementing Rave studies since 2010, and a Medidata CTMS partner for more than 5 years, SGS Life Science Services has robust and fully optimised processes in place, allowing for short set-up timelines that support the clinical team’s challenge of getting First Patient In (FPI) on time.
“Medidata Rave provides unmatched capabilities for complex designs that we manage in today’s oncology and infectious disease programmes, as well as when implementing targeted SDV,” explained Luc Braeken, Business Unit Manager Biometrics & Medical Affairs, SGS Life Science Services. “We find that our sponsors benefit greatly from data collection in Medidata Rave, with efficient data conversion to CDISC SDTM compliant datasets at the SGS Data Management center. Our goal is to empower our clients with full visibility on the study data at any moment via the eCRF, progress reports indicating the cleaning status and the CDISC SDTM datasets, which can be delivered soon after FPI.”
“Medidata Rave is a well-known system by many sites, allowing immediate data entry from FPI onwards without the hurdles and learning curve that are typically experienced with less-known EDC systems,” said Joris De Bondt, Head EDC and Data Standards, Medidata. “As a Medidata Rave accredited partner, SGS Life Science Services can offer the best, most innovative technology for clinical trials with a superior site experience. Our eCRF designers now have access to configurable work flows, sophisticated eCRF design, simple and complex edit checking and straight-forward integrations for a wide variety of data sources.”
Steve Heath, Medidata’s Head of Channel Sales, added: “Medidata’s industry-leading cloud platform of innovative technology and data analytics is transforming clinical development today — helping make clinical trials more cost effective, faster and safer. Our accreditation process assures life science companies are working with service partners that are fully equipped to use Medidata technology for optimal trial performance.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance